Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Intermittent Androgen Suppression: Estimating Parameters for Individual Patients Based on Initial PSA Data in Response to Androgen Deprivation Therapy.

Hirata Y, Morino K, Akakura K, Higano CS, Bruchovsky N, Gambol T, Hall S, Tanaka G, Aihara K.

PLoS One. 2015 Jun 24;10(6):e0130372. doi: 10.1371/journal.pone.0130372. eCollection 2015.

2.

Quantitative mathematical modeling of PSA dynamics of prostate cancer patients treated with intermittent androgen suppression.

Hirata Y, Akakura K, Higano CS, Bruchovsky N, Aihara K.

J Mol Cell Biol. 2012 Jun;4(3):127-32. doi: 10.1093/jmcb/mjs020. Epub 2012 May 4.

3.

Mathematically modelling and controlling prostate cancer under intermittent hormone therapy.

Hirata Y, Tanaka G, Bruchovsky N, Aihara K.

Asian J Androl. 2012 Mar;14(2):270-7. doi: 10.1038/aja.2011.155. Epub 2012 Jan 9. Review.

4.

Nonlinear systems identification by combining regression with bootstrap resampling.

Kuramae H, Hirata Y, Bruchovsky N, Aihara K, Suzuki H.

Chaos. 2011 Dec;21(4):043121. doi: 10.1063/1.3657919.

PMID:
22225358
5.

Hybrid optimal scheduling for intermittent androgen suppression of prostate cancer.

Hirata Y, di Bernardo M, Bruchovsky N, Aihara K.

Chaos. 2010 Dec;20(4):045125. doi: 10.1063/1.3526968.

PMID:
21198137
6.

Piecewise affine systems modelling for optimizing hormone therapy of prostate cancer.

Suzuki T, Bruchovsky N, Aihara K.

Philos Trans A Math Phys Eng Sci. 2010 Nov 13;368(1930):5045-59. doi: 10.1098/rsta.2010.0220.

7.

Mathematical modelling of prostate cancer growth and its application to hormone therapy.

Tanaka G, Hirata Y, Goldenberg SL, Bruchovsky N, Aihara K.

Philos Trans A Math Phys Eng Sci. 2010 Nov 13;368(1930):5029-44. doi: 10.1098/rsta.2010.0221. Review. Erratum in: Philos Transact A Math Phys Eng Sci. 2011 Jan 28;369(1935):495.

8.

Prostate cancer: finasteride extends PSA doubling time during intermittent hormone therapy.

Locke JA, Bruchovsky N.

Can J Urol. 2010 Jun;17(3):5162-9.

PMID:
20566007
9.

Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer.

Hirata Y, Bruchovsky N, Aihara K.

J Theor Biol. 2010 May 21;264(2):517-27. doi: 10.1016/j.jtbi.2010.02.027. Epub 2010 Feb 20.

PMID:
20176032
10.
12.
13.

Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.

Andriole G, Bruchovsky N, Chung LW, Matsumoto AM, Rittmaster R, Roehrborn C, Russell D, Tindall D.

J Urol. 2004 Oct;172(4 Pt 1):1399-403. Review.

PMID:
15371854
14.

Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells.

Blaszczyk N, Masri BA, Mawji NR, Ueda T, McAlinden G, Duncan CP, Bruchovsky N, Schweikert HU, Schnabel D, Jones EC, Sadar MD.

Clin Cancer Res. 2004 Mar 1;10(5):1860-9.

15.

Intermittent androgen suppression for prostate cancer: rationale and clinical experience.

Gleave M, Goldenberg SL, Bruchovsky N, Rennie P.

Prostate Cancer Prostatic Dis. 1998 Dec;1(6):289-296.

16.

Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells.

Ueda T, Mawji NR, Bruchovsky N, Sadar MD.

J Biol Chem. 2002 Oct 11;277(41):38087-94. Epub 2002 Aug 5.

17.

Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways.

Ueda T, Bruchovsky N, Sadar MD.

J Biol Chem. 2002 Mar 1;277(9):7076-85. Epub 2001 Dec 19.

18.

Hormones and cancer: new insights, new challenges.

Tilley WD, Clarke CL, Birrell SN, Bruchovsky N.

Trends Endocrinol Metab. 2001 Jul;12(5):186-8. No abstract available.

PMID:
11592245
19.
20.

Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations.

Bruchovsky N, Klotz LH, Sadar M, Crook JM, Hoffart D, Godwin L, Warkentin M, Gleave ME, Goldenberg SL.

Mol Urol. 2000 Fall;4(3):191-9;discussion 201.

PMID:
11062374
21.

Long-term neoadjuvant hormone therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up.

Gleave ME, La Bianca SE, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD.

Urology. 2000 Aug 1;56(2):289-94.

PMID:
10925096
22.

Clinical Experience with Intermittent Androgen Suppression in Prostate Cancer: Minimum of 3 Years' Follow-Up.

Goldenberg SL, Gleave ME, Taylor D, Bruchovsky N.

Mol Urol. 1999;3(3):287-292.

PMID:
10851335
23.

Prostate cancer: molecular biology of early progression to androgen independence.

Sadar MD, Hussain M, Bruchovsky N.

Endocr Relat Cancer. 1999 Dec;6(4):487-502. Review.

24.

[Intermittent androgen deprivation].

Tunn UW, Bruchovsky N, Renneberg H, Wolff JM, Kurek R.

Urologe A. 2000 Jan;39(1):9-13. Review. German. No abstract available.

PMID:
10663190
25.

Determinants of DNA sequence specificity of the androgen, progesterone, and glucocorticoid receptors: evidence for differential steroid receptor response elements.

Nelson CC, Hendy SC, Shukin RJ, Cheng H, Bruchovsky N, Koop BF, Rennie PS.

Mol Endocrinol. 1999 Dec;13(12):2090-107.

PMID:
10598584
26.

Discovery of the role of dihydrotestosterone in androgen action.

Bruchovsky N, Wilson JD.

Steroids. 1999 Nov;64(11):753-9. No abstract available.

PMID:
10577831
27.

Selective activation of the probasin androgen-responsive region by steroid hormones.

Kasper S, Rennie PS, Bruchovsky N, Lin L, Cheng H, Snoek R, Dahlman-Wright K, Gustafsson JA, Shiu RP, Sheppard PC, Matusik RJ.

J Mol Endocrinol. 1999 Jun;22(3):313-25.

PMID:
10343290
28.

Prostate cancer: 9. Treatment of advanced disease.

Gleave ME, Bruchovsky N, Moore MJ, Venner P.

CMAJ. 1999 Jan 26;160(2):225-32. Review.

29.

Intermittent androgen suppression for prostate cancer: rationale and clinical experience.

Gleave M, Bruchovsky N, Goldenberg SL, Rennie P.

Eur Urol. 1998;34 Suppl 3:37-41. Review.

PMID:
9854195
30.

Differential transactivation by the androgen receptor in prostate cancer cells.

Snoek R, Bruchovsky N, Kasper S, Matusik RJ, Gleave M, Sato N, Mawji NR, Rennie PS.

Prostate. 1998 Sep 1;36(4):256-63.

PMID:
9719026
31.

Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model.

Gleave ME, Sato N, Sadar M, Yago V, Bruchovsky N, Sullivan L.

J Cell Biochem. 1998 Jun 1;69(3):271-81.

PMID:
9581866
32.

Increased cystine uptake capability associated with malignant progression of Nb2 lymphoma cells.

Gout PW, Kang YJ, Buckley DJ, Bruchovsky N, Buckley AR.

Leukemia. 1997 Aug;11(8):1329-37.

PMID:
9264389
33.
34.

Mechanisms of androgen-independent tumor growth.

Goldenberg SL, Gleave ME, Bruchovsky N.

Can J Urol. 1997 Jun;4(2 Supp 1):65-67.

PMID:
12735839
35.

Re: Editorial comment.

Goldenberg SL, Gleave ME, Bruchovsky N, Rennie P.

J Urol. 1997 Jun;157(6):2267. No abstract available.

PMID:
9146650
36.

Neoadjuvant androgen withdrawal therapy decreases local recurrence rates following tumor excision in the Shionogi tumor model.

Gleave ME, Sato N, Goldenberg SL, Stothers L, Bruchovsky N, Sullivan LD.

J Urol. 1997 May;157(5):1727-30.

PMID:
9112514
37.

A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.

Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E, Sullivan LD.

Cancer Res. 1997 Apr 15;57(8):1584-9.

38.

Evaluation and follow-up of patients with N1-3 M0 or NXM1 prostate cancer in phase III trials.

Hall R, Hedlund PO, Ackermann R, Bruchovsky N, Dalesio O, Debruyne F, Murphy GP, Parmar MK, Pavone-Macaluso M, Ruutu M, Smith P.

Urology. 1997 Apr;49(4A Suppl):39-45.

PMID:
9111613
39.

Effects of intermittent androgen suppression on the stem cell composition and the expression of the TRPM-2 (clusterin) gene in the Shionogi carcinoma.

Akakura K, Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, Tenniswood M, Fox K.

J Steroid Biochem Mol Biol. 1996 Dec;59(5-6):501-11.

PMID:
9010356
40.

Characterization of 5alpha-reductase gene expression in stroma and epithelium of human prostate.

Bruchovsky N, Sadar MD, Akakura K, Goldenberg SL, Matsuoka K, Rennie PS.

J Steroid Biochem Mol Biol. 1996 Dec;59(5-6):397-404.

PMID:
9010345
41.

Induction of cell-free, in vitro transcription by recombinant androgen receptor peptides.

Snoek R, Rennie PS, Kasper S, Matusik RJ, Bruchovsky N.

J Steroid Biochem Mol Biol. 1996 Nov;59(3-4):243-50.

PMID:
9010316
42.

[Hormone release and intermittent hormonal therapy in the LN CaP model of human prostate cancer].

Gleave M, Santo N, Rennie PS, Goldenberg SL, Bruchovsky N, Sullivan LD.

Prog Urol. 1996 Jun;6(3):375-85. French.

PMID:
8763692
43.

Low-dose cyproterone acetate plus mini-dose diethylstilbestrol--a protocol for reversible medical castration.

Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD.

Urology. 1996 Jun;47(6):882-4.

PMID:
8677581
44.

Characterization of type I 5 alpha-reductase activity in DU145 human prostatic adenocarcinoma cells.

Kaefer M, Audia JE, Bruchovsky N, Goode RL, Hsiao KC, Leibovitch IY, Krushinski JH, Lee C, Steidle CP, Sutkowski DM, Neubauer BL.

J Steroid Biochem Mol Biol. 1996 May;58(2):195-205.

PMID:
8809201
45.

Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model.

Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH, Sullivan LD.

J Steroid Biochem Mol Biol. 1996 May;58(2):139-46.

PMID:
8809195
46.

Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer.

Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Kinahan J, Sullivan LD.

Semin Urol Oncol. 1996 May;14(2 Suppl 2):39-45; discussion 46-7. Review.

PMID:
8725890
47.

Control of tumor progression by maintenance of apoptosis.

Bruchovsky N, Snoek R, Rennie PS, Akakura K, Goldenberg LS, Gleave M.

Prostate Suppl. 1996;6:13-21. Review.

PMID:
8630223
48.
49.

[Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma].

Bruchovsky N, Goldenberg SL, Rennie PS, Gleave M.

Urologe A. 1995 Sep;34(5):389-92. Review. German.

PMID:
7483155
50.

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.

Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K.

Urology. 1995 May;45(5):839-44; discussion 844-5.

PMID:
7538246

Supplemental Content

Loading ...
Support Center